Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Arcellx

Arcellx Shows Improved Relative Strength; Still Shy Of Benchmark

Arcellx shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Arcellx Scores Relative Strength Rating Upgrade; Hits Key Benchmark

Arcellx shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 83.

Investors Business Daily

Arcellx Sees Relative Strength Rating Improve To 73

A Relative Strength Rating upgrade for Arcellx shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Arcellx Trying To Close In On Key Technical Benchmark

Arcellx shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Arcellx Trying To Close In On Key Technical Measure

A Relative Strength Rating upgrade for Arcellx shows improving technical performance. Will it continue?

Investors Business Daily

Arcellx Stock Earns 82 Relative Strength Rating

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Investors Business Daily

In-Depth Examination Of 14 Analyst Recommendations For Arcellx

In the last three months, 14 analysts have published ratings on Arcellx (NASDAQ:ACLX), offering a diverse range of perspectives from bullish to bearish.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.

Investors Business Daily

14 Analysts Have This To Say About Arcellx

In the latest quarter, 14 analysts provided ratings for Arcellx (NASDAQ:ACLX), showcasing a mix of bullish and bearish perspectives.

Benzinga

2 Potential Stocks to Buy From Barchart’s ‘Death Cross’ Indicator

While a security’s short-term moving average dipping below its long-term average warrants caution, this dynamic may also be a contrarian indicator.

Barchart

Arcellx Stock Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Arcellx shows improving technical performance.

Investors Business Daily

GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

StockNews.com

These Stocks Are Exploding In The November Stock Market Rally

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

Investors Business Daily

Dow Jones Jumps Another 160 Points Amid More Evidence Inflation Is Waning

After a red letter day on the stock market, investor enthusiasm kept climbing on the Dow Jones index as all major indexes piled on gains.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday. ACLX stock rocketed into a breakout.

Investors Business Daily

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death

The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.

Investors Business Daily

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying

Although the US stocks closed higher on Thursday, there were a few notable insider trades.

Investors Business Daily

How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer

Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.

Benzinga

Expert Ratings for Arcellx

Analysts have provided the following ratings for Arcellx (NASDAQ:ACLX) within the last quarter:

Benzinga

Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma

Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).

Benzinga

BofA Initiates Arcellx With Buy On Its Novel Therapy Approach

Arcellx (NASDAQ: ACLX) is advancing into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known as ddBCMA, for relapsed refractory multiple myeloma, according to BofA Securities.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Upgrades

Benzinga

CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19

CAR-T company Arcellx Inc (NASDAQ: ACLX) priced its IPO at

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.